<DOC>
	<DOCNO>NCT00002936</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness altretamine plus etoposide treating patient HIV-related cancer .</brief_summary>
	<brief_title>Altretamine Etoposide Treating Patients With HIV-Related Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxic effect repeat course altretamine plus etoposide maximum tolerate dose ( MTD ) . II . Assess response duration time progression MTD treatment HIV malignancy . III . Assess efficacy combination immune system individual . IV . Assess effect combination quality life individual . OUTLINE : Patients treat altretamine ( HMM ) etoposide 2 week follow 2 week rest . This cycle repeat minimum 2 maximum 6 cycle progression disease . Patients complete remission receive additional 2 cycle ( total 8 cycle ) . There different cohort consist 4 patient toxic effect evaluate escalate dos combination . The MTD define dose level immediately half patient experience dose-limiting toxicity . Patients follow relapse survival . PROJECTED ACCRUAL : 20 patient accrue 2 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Altretamine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Documented HIV antibody positive Histologically confirm , biopsy , nonHodgkin 's lymphoma complete remission stable/partial remission minimal period one month And/or Histologically confirm , biopsy , Kaposi 's sarcoma without stable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Hematopoietic : Absolute neutrophil count least 500/mm3 Platelet count great 25,000/mm3 ( unless secondary lymphoma ) Hepatic : Transaminases less 5 time upper limit normal AND Bilirubin less 2.0 , unless secondary lymphoma Renal : Creatinine le 2.0 mg/dL OR Creatinine clearance least 60 mL/min Dose reduction 21 % creatinine clearance 1050 mL/min Dose reduction 50 % creatinine clearance le 10 mL/min Cardiovascular : No active cardiac arrhythmia angina Pulmonary : Must exclude Pneumocystis carinii pneumonia suspicion infection Other : No uncontrolled infection Not pregnant nursing Adequate contraception fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Patients concurrent antiretroviral therapy stable dose therapy least one month prior entry No concurrent cytotoxic chemotherapy Endocrine therapy : No concurrent hormone therapy Radiotherapy : No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
	<keyword>recurrent Kaposi sarcoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
</DOC>